share_log

藥明生物：截至2024年2月29日止股份發行人的證券變動月報表

WUXI BIO: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 29 February 2024

香港交易所 ·  Mar 6 06:15
Summary by Moomoo AI
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年3月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股份變動情況。報告顯示，公司的法定/註冊股本在過去一個月內未有變動，結存維持在6,000,000,000股，每股面值為USD1/120,000，法定/註冊股本總額為50,000美元。此外，根據公司的股份期權計劃，包括首次公開發售前購股權計劃及其他股份獎勵計劃，本月底結存的股份期權數目未見變動，維持在114,041,208股。報告亦提到，公司於2024年2月5日、6日及7日購回合共37,556,500股普通股，以及於2024年1月16日至19日購回合共10,091,500股普通股，另於2023年12月購回合共34,769,000股普通股，但這些股份於報告截至日尚未註銷。藥明生物確認，所有證券的發行均已獲得董事會正式授權批准，並符合相關上市規則的要求。
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年3月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股份變動情況。報告顯示，公司的法定/註冊股本在過去一個月內未有變動，結存維持在6,000,000,000股，每股面值為USD1/120,000，法定/註冊股本總額為50,000美元。此外，根據公司的股份期權計劃，包括首次公開發售前購股權計劃及其他股份獎勵計劃，本月底結存的股份期權數目未見變動，維持在114,041,208股。報告亦提到，公司於2024年2月5日、6日及7日購回合共37,556,500股普通股，以及於2024年1月16日至19日購回合共10,091,500股普通股，另於2023年12月購回合共34,769,000股普通股，但這些股份於報告截至日尚未註銷。藥明生物確認，所有證券的發行均已獲得董事會正式授權批准，並符合相關上市規則的要求。
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) filed with Hong Kong Trading and Clearing Limited on 6 March 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 29 February 2024. The report shows that the company's regulary/registered share capital remained unchanged over the past month, with deposits held at 6,000,000,000 shares with a face value of USD1/120,000 per share and a total regulated/registered share capital of $50,000. In addition, the number of stock options outstanding at the end of the month remained unchanged at 114,041,208 shares under the Company's stock option plan, which includes the Initial Public Offering Option Plan and other share award programs. The report also noted that the Company...Show More
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) filed with Hong Kong Trading and Clearing Limited on 6 March 2024 with Hong Kong Trading and Settlement Limited, reporting the changes in the company's shares for the year ended 29 February 2024. The report shows that the company's regulary/registered share capital remained unchanged over the past month, with deposits held at 6,000,000,000 shares with a face value of USD1/120,000 per share and a total regulated/registered share capital of $50,000. In addition, the number of stock options outstanding at the end of the month remained unchanged at 114,041,208 shares under the Company's stock option plan, which includes the Initial Public Offering Option Plan and other share award programs. The report also noted that the Company purchased a total of 37,556,500 shares of ordinary shares on February 5, 6 and 7, 2024, and a total of 10,091,500 shares of ordinary shares from January 16 to 19, 2024, and a total of 34,769,000 ordinary shares in December 2023, but these shares have not been withdrawn as of the reporting date. Pharmacio confirms that all issuance of the securities has been formally authorized by the Board of Directors and complies with the requirements of the relevant Listing Rules.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more